Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Study Details
Study Description
Brief Summary
This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention, to learn whether the drug works in treating a specific disease, in this case, clofarabine to treat LCH.
"Investigational" means that the intervention is still being studied. It also means that the FDA (the U.S. Food and Drug Administration) has not yet approved clofarabine for your disease.
Clofarabine is a chemotherapy drug that has been used and is approved by the FDA for the treatment of leukemia in children and adults. Information from other research studies suggests that this drug may also be effective in participants with LCH and other histiocytic disorders.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
Drug: Clofarabine
second-generation purine nucleoside analog
Other Names:
|
| Experimental: LCH-related disorders + Clofarabine Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
Drug: Clofarabine
second-generation purine nucleoside analog
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Response Rate (OR) of LCH Cohort [Disease was evaluated at baseline and the end of cycle 2. Treatment continued after cycle 2 until disease progression or unacceptable toxicity. LCH treatment duration has a median of 5.8 months with range 2.1-7 months.]
The OR was defined as the proportion of participants achieving certain response on treatment among LCH patients, criteria were defined per protocol. Better response were defined as achieving complete disease resolution (NAD) or disease regression (AD better); intermediate response defined as stable or unchanged disease status; worse response defined as disease progression.
- Response Rate of LCH-related Disorders Cohort [Disease was evaluated at baseline and the end of cycle 2. Treatment continued after cycle 2 until disease progression or unacceptable toxicity. Treatment duration has a median of 5.5 months with range 1.7-5.6 months.]
The OR was defined as the proportion of participants achieving certain response on treatment among LCH-related disorder patients, criteria were defined per protocol. A clinical response of progressive metabolic disease (PMD) defined as CT-based target lesion abnormal and bone marrow new or recurrent involvement; partial metabolic response (PMR) defined as CT-based target lesion decreasing or disease regressed.
Secondary Outcome Measures
- 1-year Progression Free Survival (PFS) [At 1 year]
1-year PFS defined as the proportion of patients that survival progression free at 1 year. PFS based on the duration of time from study entry to documented disease progression (PD) or death. Per protocol criteria: where time to event for PFS is the time from study enrollment until the time of first occurrence of new lesions, progressive disease, or death from any cause, or until last contact if no event occurs.
- 1-year Overall Survival (OS) [At 1 year]
1-year OS defined as the proportion of patients that survival at 1 year. OS calculated as the time from enrollment until death or censored at date last known alive.
- Number of Participants With at Least One Grade 3 or Higher Treatment-Related Toxicity [Disease was evaluated at baseline and the end of cycle 2. Treatment continued after cycle 2 until disease progression or unacceptable toxicity. LCH treatment duration is median 5.8 with range 2.1-7 months; LCH-related treatment duration is 5.5 (1.7-5.6).]
All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv4.0 as reported on case report forms were counted. Number of Participants with at least one Grade 3 or Higher Treatment-Related Toxicity defined as number of patients experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Prior diagnosis of Langerhans Cell Histiocytosis (stratum 1) or LCH-related disorder (stratum 2) established by standard diagnostic criteria and confirmed histologically.
-
Evidence of active disease (histological confirmation of reactivation or progression is not required).
-
Performance Score > 70% (use Lansky score for age < 16 and Karnofsky score for age =
16).
-
Patients of all ages will be eligible.
-
Provide signed written informed consent.
-
In stratum 1, patients must have failed one prior systemic chemotherapy regimen. In stratum 2, RDD patients must have failed treatment with corticosteroid. ECD patients who have confirmed BRAF V600E mutation must have failed treatment with a BRAF inhibitor or are not considered to be eligible for such treatment.
-
There is no limitation of amount or the type of prior therapy or drugs.
-
Female patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
-
Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
-
Participants must have adequate marrow functions as defined below, except those with involvement of hematopoietic system for whom these criteria can be waived:
-
Absolute neutrophil count ≥ 750 cells/µL
-
Platelets ≥75,000/µL
-
Participants must have adequate organ functions as defined below:
-
Total bilirubin ≤ 2.5x institutional upper limit of normal
-
AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal unless it is related to involvement by LCH
-
Adequate renal function defined as:
-
Pediatric Population (patients < 18 years): Creatinine within normal limits or calculated creatinine clearance greater than or equal to 90 ml/min/1.73 m2 as calculated by the Schwartz formula for estimated glomerular filtration rate (GFR) where GFR (ml/min/1.73 m2) = k x Height (cm)/serum creatinine (mg/dl). k is a proportionality constant which varies with age and is a function of urinary creatinine excretion per unit of body size; 0.45 up to 12 months of age; 0.55 children and adolescent girls; and 0.70 adolescent boys.
-
Adult Population (patients >= 18 years): Serum creatinine less than or equal to 1.0 mg/dL; if serum creatinine >1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be >60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2) = 186 x (Serum Creatinine)-1.154 x (age in years)-0.203 x (0.742 if patient is female) x (1.212 if patient is black), where serum creatinine is measured in mg/dL.
-
Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal
Exclusion Criteria:
-
Participants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Corticosteroid treatment is allowed.
-
Participants may not be receiving any other investigational agents targeting Histiocytosis.
-
Clofarabine is excreted primarily by the kidneys. Therefore, drugs with known renal toxicity (e.g.vancomycin, amphotericin B, acyclovir, cyclosporin, methotrexate, tacrolimus) should be avoided to the extent possible during the 5 days of clofarabine treatment in each cycle or, if required, administered cautiously and with close monitoring.
-
Use of alternative medications (e.g., herbal or botanical that could interfere with clofarabine) is not permitted during the entire study period.
-
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Pregnant women are excluded from this study because clofarabine is a nucleoside analog with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with clofarabine, breastfeeding should be discontinued if the mother is treated with clofarabine. These potential risks may also apply to other agents used in this study.
-
Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
-
Patients with a history of prior hematopoietic stem cell transplantation (HSCT), elevated conjugated serum bilirubin at study entry, uncontrolled systemic fungal, bacterial, or other infection, a history of hepatitis B or C infection or a history of cirrhosis.
-
Individuals who are known to be HIV-positive on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with clofarabine. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Phoenix Children's Hospital | Phoenix | Arizona | United States | 85016 |
| 2 | Arkansas Children's Hospital | Little Rock | Arkansas | United States | 72202 |
| 3 | Children's Hospital of Los Angeles | Los Angeles | California | United States | 90027 |
| 4 | University of California San Francisco Medical Center | San Francisco | California | United States | 94143 |
| 5 | Children's National Medical Center | Washington | District of Columbia | United States | 20010 |
| 6 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
| 7 | Boston Children's Hospital | Boston | Massachusetts | United States | 02115 |
| 8 | Dana-Farber Cancer Institute | Boston | Massachusetts | United States | 02115 |
| 9 | Dana-Farber Cancer Institute | Boston | Massachusetts | United States | 02215 |
| 10 | Mount Sinai Medical Center | New York | New York | United States | 10029 |
| 11 | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States | 45229 |
| 12 | The Children's Hospital of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 |
| 13 | St. Jude Children's Research Hospital | Memphis | Tennessee | United States | 38105 |
| 14 | Texas Children's Hospital | Houston | Texas | United States | 77030 |
| 15 | The Hospital for Sick Children | Toronto | Ontario | Canada | M5G 1X8 |
Sponsors and Collaborators
- Dana-Farber Cancer Institute
- Sanofi
- St. Baldrick's Foundation
- Cookies for Kids' Cancer
- North American Consortium for Histiocytosis
Investigators
- Principal Investigator: Barbara Degar, MD, Dana-Farber Cancer Institute
Study Documents (Full-Text)
More Information
Publications
None provided.- 15-005
Study Results
Participant Flow
| Recruitment Details | from 5/21/2015 to 1/14/2020 |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine |
|---|---|---|
| Arm/Group Description | Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. | Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
| Period Title: Overall Study | ||
| STARTED | 20 | 5 |
| Efficacy Analysis | 20 | 4 |
| COMPLETED | 17 | 2 |
| NOT COMPLETED | 3 | 3 |
Baseline Characteristics
| Arm/Group Title | Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine | Total |
|---|---|---|---|
| Arm/Group Description | Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. | Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. | Total of all reporting groups |
| Overall Participants | 20 | 5 | 25 |
| Age, Customized (years) [Median (Full Range) ] | |||
| Median (Full Range) [years] |
3.4
|
38.6
|
4.3
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
15
75%
|
2
40%
|
17
68%
|
| Male |
5
25%
|
3
60%
|
8
32%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||
| Hispanic or Latino |
3
15%
|
0
0%
|
3
12%
|
| Not Hispanic or Latino |
15
75%
|
5
100%
|
20
80%
|
| Unknown or Not Reported |
2
10%
|
0
0%
|
2
8%
|
| Region of Enrollment (participants) [Number] | |||
| United States |
17
85%
|
5
100%
|
22
88%
|
| Canada |
3
15%
|
0
0%
|
3
12%
|
Outcome Measures
| Title | Response Rate (OR) of LCH Cohort |
|---|---|
| Description | The OR was defined as the proportion of participants achieving certain response on treatment among LCH patients, criteria were defined per protocol. Better response were defined as achieving complete disease resolution (NAD) or disease regression (AD better); intermediate response defined as stable or unchanged disease status; worse response defined as disease progression. |
| Time Frame | Disease was evaluated at baseline and the end of cycle 2. Treatment continued after cycle 2 until disease progression or unacceptable toxicity. LCH treatment duration has a median of 5.8 months with range 2.1-7 months. |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine |
|---|---|
| Arm/Group Description | Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
| Measure Participants | 20 |
| Better |
0.85
4.3%
|
| Intermediate |
0.15
0.8%
|
| Worse |
0
0%
|
| Title | Response Rate of LCH-related Disorders Cohort |
|---|---|
| Description | The OR was defined as the proportion of participants achieving certain response on treatment among LCH-related disorder patients, criteria were defined per protocol. A clinical response of progressive metabolic disease (PMD) defined as CT-based target lesion abnormal and bone marrow new or recurrent involvement; partial metabolic response (PMR) defined as CT-based target lesion decreasing or disease regressed. |
| Time Frame | Disease was evaluated at baseline and the end of cycle 2. Treatment continued after cycle 2 until disease progression or unacceptable toxicity. Treatment duration has a median of 5.5 months with range 1.7-5.6 months. |
Outcome Measure Data
| Analysis Population Description |
|---|
| 1 patient excluded because of problematic enrollment |
| Arm/Group Title | LCH-related Disorders + Clofarabine |
|---|---|
| Arm/Group Description | Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
| Measure Participants | 4 |
| PMR |
0.75
3.8%
|
| PMD |
0.26
1.3%
|
| Title | 1-year Progression Free Survival (PFS) |
|---|---|
| Description | 1-year PFS defined as the proportion of patients that survival progression free at 1 year. PFS based on the duration of time from study entry to documented disease progression (PD) or death. Per protocol criteria: where time to event for PFS is the time from study enrollment until the time of first occurrence of new lesions, progressive disease, or death from any cause, or until last contact if no event occurs. |
| Time Frame | At 1 year |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine |
|---|---|---|
| Arm/Group Description | Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. | Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
| Measure Participants | 20 | 4 |
| Number [proportion of patients] |
0.89
|
0.5
|
| Title | 1-year Overall Survival (OS) |
|---|---|
| Description | 1-year OS defined as the proportion of patients that survival at 1 year. OS calculated as the time from enrollment until death or censored at date last known alive. |
| Time Frame | At 1 year |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine |
|---|---|---|
| Arm/Group Description | Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. | Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
| Measure Participants | 20 | 4 |
| Number [proportion of patients] |
1
|
0.75
|
| Title | Number of Participants With at Least One Grade 3 or Higher Treatment-Related Toxicity |
|---|---|
| Description | All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv4.0 as reported on case report forms were counted. Number of Participants with at least one Grade 3 or Higher Treatment-Related Toxicity defined as number of patients experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation. |
| Time Frame | Disease was evaluated at baseline and the end of cycle 2. Treatment continued after cycle 2 until disease progression or unacceptable toxicity. LCH treatment duration is median 5.8 with range 2.1-7 months; LCH-related treatment duration is 5.5 (1.7-5.6). |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine |
|---|---|---|
| Arm/Group Description | Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. | Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. |
| Measure Participants | 20 | 4 |
| Count of Participants [Participants] |
15
75%
|
4
80%
|
Adverse Events
| Time Frame | Adverse events are assessed every cycle until the end of treatment. LCH Cohort treatment duration has a median of 5.8 months with range 2.1-7 months. LCH-related Disorders Cohort Treatment duration has a median of 5.5 months with range 1.7-5.6 months. | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | Serious adverse events (AEs) were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv4. All remaining events regardless of treatment attribution were classified as Other AEs. Maximum grade toxicity by type for a patient over time was calculated. No further data is available to specify classification of other beyond the general term. | |||
| Arm/Group Title | Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine | ||
| Arm/Group Description | Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. Clofarabine: second-generation purine nucleoside analog | Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor. Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles. Clofarabine: second-generation purine nucleoside analog | ||
All Cause Mortality |
||||
| Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/20 (0%) | 3/4 (75%) | ||
Serious Adverse Events |
||||
| Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 15/20 (75%) | 4/4 (100%) | ||
| Blood and lymphatic system disorders | ||||
| Anemia | 8/20 (40%) | 4/4 (100%) | ||
| Febrile neutropenia | 6/20 (30%) | 2/4 (50%) | ||
| Gastrointestinal disorders | ||||
| Mucositis oral | 1/20 (5%) | 0/0 (NaN) | ||
| Oral pain | 1/20 (5%) | 0/0 (NaN) | ||
| Vomiting | 1/20 (5%) | 0/0 (NaN) | ||
| Infections and infestations | ||||
| Device related infection | 1/20 (5%) | 0/0 (NaN) | ||
| Lung infection | 0/0 (NaN) | 1/4 (25%) | ||
| Mucosal infection | 1/20 (5%) | 0/0 (NaN) | ||
| Urinary tract infection | 1/20 (5%) | 0/0 (NaN) | ||
| Investigations | ||||
| Alanine aminotransferase increased | 1/20 (5%) | 1/4 (25%) | ||
| Aspartate aminotransferase increased | 1/20 (5%) | 1/4 (25%) | ||
| Lymphocyte count decreased | 3/20 (15%) | 1/4 (25%) | ||
| Neutrophil count decreased | 8/20 (40%) | 2/4 (50%) | ||
| Platelet count decreased | 3/20 (15%) | 4/4 (100%) | ||
| White blood cell decreased | 4/20 (20%) | 2/4 (50%) | ||
| Metabolism and nutrition disorders | ||||
| Hyperkalemia | 1/20 (5%) | 0/0 (NaN) | ||
| Hyponatremia | 0/0 (NaN) | 1/4 (25%) | ||
| Skin and subcutaneous tissue disorders | ||||
| Urticaria | 1/20 (5%) | 0/0 (NaN) | ||
Other (Not Including Serious) Adverse Events |
||||
| Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine | LCH-related Disorders + Clofarabine | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 20/20 (100%) | 4/4 (100%) | ||
| Blood and lymphatic system disorders | ||||
| Anemia | 5/20 (25%) | 2/4 (50%) | ||
| Blood and lymphatic system disorders - Other, specify | 3/20 (15%) | 1/4 (25%) | ||
| Cardiac disorders | ||||
| Cardiac disorders - Other, specify | 1/20 (5%) | 0/0 (NaN) | ||
| Palpitations | 0/0 (NaN) | 1/4 (25%) | ||
| Sinus tachycardia | 7/20 (35%) | 0/0 (NaN) | ||
| Ear and labyrinth disorders | ||||
| Ear and labyrinth disorders - Other, specify | 2/20 (10%) | 0/0 (NaN) | ||
| Ear pain | 4/20 (20%) | 0/0 (NaN) | ||
| Hearing impaired | 2/20 (10%) | 0/0 (NaN) | ||
| Endocrine disorders | ||||
| Endocrine disorders - Other, specify | 3/20 (15%) | 0/0 (NaN) | ||
| Hypothyroidism | 0/0 (NaN) | 1/4 (25%) | ||
| Eye disorders | ||||
| Conjunctivitis | 1/20 (5%) | 0/0 (NaN) | ||
| Eye disorders - Other, specify | 1/20 (5%) | 0/0 (NaN) | ||
| Scleral disorder | 1/20 (5%) | 0/0 (NaN) | ||
| Gastrointestinal disorders | ||||
| Abdominal distension | 1/20 (5%) | 0/0 (NaN) | ||
| Abdominal pain | 4/20 (20%) | 1/4 (25%) | ||
| Anal pain | 1/20 (5%) | 0/0 (NaN) | ||
| Constipation | 11/20 (55%) | 1/4 (25%) | ||
| Dental caries | 1/20 (5%) | 0/0 (NaN) | ||
| Diarrhea | 7/20 (35%) | 0/0 (NaN) | ||
| Duodenal hemorrhage | 1/20 (5%) | 0/0 (NaN) | ||
| Gastrointestinal disorders - Other, specify | 2/20 (10%) | 0/0 (NaN) | ||
| Lip pain | 1/20 (5%) | 0/0 (NaN) | ||
| Mucositis oral | 2/20 (10%) | 1/4 (25%) | ||
| Nausea | 11/20 (55%) | 3/4 (75%) | ||
| Rectal hemorrhage | 1/20 (5%) | 0/0 (NaN) | ||
| Rectal pain | 1/20 (5%) | 0/0 (NaN) | ||
| Vomiting | 12/20 (60%) | 2/4 (50%) | ||
| General disorders | ||||
| Edema face | 0/0 (NaN) | 1/4 (25%) | ||
| Edema limbs | 1/20 (5%) | 0/0 (NaN) | ||
| Edema trunk | 1/20 (5%) | 0/0 (NaN) | ||
| Fatigue | 9/20 (45%) | 3/4 (75%) | ||
| Fever | 10/20 (50%) | 2/4 (50%) | ||
| Flu like symptoms | 2/20 (10%) | 0/0 (NaN) | ||
| Gait disturbance | 1/20 (5%) | 0/0 (NaN) | ||
| Irritability | 2/20 (10%) | 0/0 (NaN) | ||
| Localized edema | 0/0 (NaN) | 1/4 (25%) | ||
| Pain | 1/20 (5%) | 2/4 (50%) | ||
| Immune system disorders | ||||
| Allergic reaction | 2/20 (10%) | 0/0 (NaN) | ||
| Infections and infestations | ||||
| Eye infection | 1/20 (5%) | 0/0 (NaN) | ||
| Infections and infestations - Other, specify | 1/20 (5%) | 1/4 (25%) | ||
| Lip infection | 1/20 (5%) | 0/0 (NaN) | ||
| Otitis media | 2/20 (10%) | 0/0 (NaN) | ||
| Upper respiratory infection | 1/20 (5%) | 0/0 (NaN) | ||
| Injury, poisoning and procedural complications | ||||
| Tracheal obstruction | 1/20 (5%) | 0/0 (NaN) | ||
| Investigations | ||||
| Alanine aminotransferase increased | 0/0 (NaN) | 1/4 (25%) | ||
| Alkaline phosphatase increased | 0/0 (NaN) | 1/4 (25%) | ||
| Aspartate aminotransferase increased | 1/20 (5%) | 2/4 (50%) | ||
| Blood bilirubin increased | 1/20 (5%) | 1/4 (25%) | ||
| Creatinine increased | 1/20 (5%) | 0/0 (NaN) | ||
| Lymphocyte count decreased | 1/20 (5%) | 1/4 (25%) | ||
| Neutrophil count decreased | 2/20 (10%) | 0/0 (NaN) | ||
| Platelet count decreased | 3/20 (15%) | 2/4 (50%) | ||
| Weight gain | 1/20 (5%) | 0/0 (NaN) | ||
| Weight loss | 1/20 (5%) | 1/4 (25%) | ||
| White blood cell decreased | 2/20 (10%) | 0/0 (NaN) | ||
| Metabolism and nutrition disorders | ||||
| Anorexia | 3/20 (15%) | 1/4 (25%) | ||
| Hyperglycemia | 4/20 (20%) | 1/4 (25%) | ||
| Hypernatremia | 0/0 (NaN) | 1/4 (25%) | ||
| Hypoalbuminemia | 0/0 (NaN) | 2/4 (50%) | ||
| Hypocalcemia | 0/0 (NaN) | 1/4 (25%) | ||
| Hypokalemia | 0/0 (NaN) | 1/4 (25%) | ||
| Hyponatremia | 2/20 (10%) | 0/0 (NaN) | ||
| Obesity | 1/20 (5%) | 0/0 (NaN) | ||
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 2/20 (10%) | 0/0 (NaN) | ||
| Back pain | 3/20 (15%) | 1/4 (25%) | ||
| Bone pain | 1/20 (5%) | 0/0 (NaN) | ||
| Myalgia | 2/20 (10%) | 0/0 (NaN) | ||
| Pain in extremity | 4/20 (20%) | 1/4 (25%) | ||
| Nervous system disorders | ||||
| Ataxia | 1/20 (5%) | 0/0 (NaN) | ||
| Headache | 4/20 (20%) | 1/4 (25%) | ||
| Neuralgia | 1/20 (5%) | 0/0 (NaN) | ||
| Tremor | 1/20 (5%) | 0/0 (NaN) | ||
| Psychiatric disorders | ||||
| Agitation | 1/20 (5%) | 0/0 (NaN) | ||
| Anxiety | 2/20 (10%) | 1/4 (25%) | ||
| Confusion | 0/0 (NaN) | 1/4 (25%) | ||
| Depression | 1/20 (5%) | 1/4 (25%) | ||
| Insomnia | 1/20 (5%) | 0/0 (NaN) | ||
| Renal and urinary disorders | ||||
| Proteinuria | 1/20 (5%) | 0/0 (NaN) | ||
| Urinary incontinence | 1/20 (5%) | 0/0 (NaN) | ||
| Urinary tract pain | 1/20 (5%) | 0/0 (NaN) | ||
| Reproductive system and breast disorders | ||||
| Vaginal pain | 1/20 (5%) | 0/0 (NaN) | ||
| Respiratory, thoracic and mediastinal disorders | ||||
| Allergic rhinitis | 2/20 (10%) | 0/0 (NaN) | ||
| Cough | 8/20 (40%) | 0/0 (NaN) | ||
| Dyspnea | 1/20 (5%) | 1/4 (25%) | ||
| Epistaxis | 1/20 (5%) | 1/4 (25%) | ||
| Voice alteration | 0/0 (NaN) | 1/4 (25%) | ||
| Skin and subcutaneous tissue disorders | ||||
| Dry skin | 3/20 (15%) | 0/0 (NaN) | ||
| Pruritus | 3/20 (15%) | 0/0 (NaN) | ||
| Rash maculo-papular | 7/20 (35%) | 1/4 (25%) | ||
| Scalp pain | 1/20 (5%) | 0/0 (NaN) | ||
| Skin and subcutaneous tissue disorders - Other, specify | 1/20 (5%) | 0/0 (NaN) | ||
| Vascular disorders | ||||
| Hypertension | 2/20 (10%) | 1/4 (25%) | ||
| Hypotension | 2/20 (10%) | 0/0 (NaN) | ||
| Thromboembolic event | 1/20 (5%) | 0/0 (NaN) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Barbara Degar, MD |
|---|---|
| Organization | Dana-Farber Cancer Institute/Boston Children's Hospital |
| Phone | 617-632-5186 |
| Barbara_Degar@dfci.harvard.edu |
- 15-005